Sign inJoin waitlistJoin the waitlist

Helen Ross

Interim Division Chief · Rush University Medical Center

Credentials: · · · · · · · ·

History

Rush University Medical Center
Present
Cancer Research & Clinical Trials · Rush University Medical Center
Present
Rush University Medical Center
Present

University of California-Los Angeles
1988–1990
Ronald Reagan UCLA Medical Center
1987–1988
Internal Medicine
Cedars-Sinai Medical Center
1984–1987
UCLA David Geffen School of Medicine
1980–1984

Research

Multiple transport pathways for neutral amino acids in rabbit jejunal brush border vesicles
The Journal of Membrane Biology · 1982 · 304 citations
Expert Consensus Document on Pulmonary Metastasectomy
Review · The Annals of Thoracic Surgery · 2019 · 168 citations
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non…
Journal of Clinical Oncology · 2007 · 166 citations

Dawn Jaroszewski
9 papers · 3 as a resident
SS
Steven Schild
9 papers
HP
Harshita Paripati
8 papers
Jonathan Ashman
6 papers
CO
Coleman Obasaju
5 papers
Corey Langer
5 papers
Terence Sio
5 papers
Alex Adjei
4 papers
CB
Chandra Belani
4 papers
Kristi Harold
4 papers
Thomas Daniels
4 papers
William Rule
4 papers

Grants

Cyclosporine Enhancement of Paclitaxel in Lung Cancer
National Cancer Institute · R01
Contact PI · $753K · Oregon Health & Science University
1996–2002
Regulation of Cytokine Mrna Stability in Tumor Cells
National Cancer Institute · K11
Contact PI · $405.8K · University of California-Irvine
1991–1996

Clinical trials

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Study chair · Active not recruiting · Phase 2
Alliance Foundation Trials, LLC.
2023–2026
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Study chair · Completed · Phase 2
Alliance Foundation Trials, LLC.
2017–2022
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2028
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2019–2029